醒脑静注射液联合尿激酶治疗高血压脑出血的临床研究  

Clinical study on Xingnaojing Injection combined with urokinase in treatment of hypertensive cerebral hemorrhage

作　　者：靳冬[1] 王晶[2] JIN Dong;WANG Jing(Department of Traditional Chinese Medicine, Affiliated Hospital of Armed Police Logistics College, Tianjin 300162, China;Department of Acupuncture and Moxibustion, Second Affiliated Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin 300143, China)

机构地区：[1]武警后勤学院附属医院中医科,天津300162 [2]天津中医药大学第二附属医院针灸科,天津300143

出　　处：《现代药物与临床》2018年第6期1342-1346,共5页Drugs & Clinic

摘　　要：目的探讨醒脑静注射液联合注射用尿激酶治疗高血压脑出血的临床疗效。方法选取2015年1月—2016年6月武警后勤学院附属医院收治的高血压脑出血患者84例为研究对象,采用Excel表法随机分为对照组和治疗组,每组各42例。两组采用微创引流穿刺术,向血肿腔内注入注射用尿激酶,10万单位加入到生理盐水5 m L中,保留2~3 h后引流。待血肿清除后拔管(5 d左右)。术后对照组静脉滴注5%葡萄糖注射液250 m L,1次/d;治疗组在对照组的基础上术后静脉滴注醒脑静注射液,20 m L加入到生理盐水250 m L中,1次/d。两组患者均持续治疗4周。观察两组的临床疗效,比较两组的美国国立卫生研究院脑卒中量表(NIHSS)评分和血清学指标。结果治疗后,对照组和治疗组的总有效率分别为81.0%、92.9%,两组比较差异有统计学意义(P<0.05)。治疗后,两组NIHSS评分均显著下降,同组治疗前后比较差异有统计学意义(P<0.05);且治疗组NIHSS评分明显低于对照组,两组比较差异具有统计学意义(P<0.05)。治疗后,两组血清C-反应蛋白(CRP)、肿瘤坏死因子-α(TNF-α)和巨噬细胞转移抑制因子(MIF)水平均显著下降,胰岛素样生长因子-1(IGF-1)水平显著升高,同组治疗前后比较差异有统计学意义(P<0.05);且治疗组这些血清学指标的改善程度明显优于对照组,两组比较差异具有统计学意义(P<0.05)。结论醒脑静注射液联合注射用尿激酶治疗高血压脑出血具有较好的疗效,能改善神经功能,降低血清炎症水平,具有一定的临床推广应用价值。Objective To investigate the clinical effect of Xingnaojing Injection combined with Urokinase for injection in treatment of hypertensive cerebral hemorrhage. Methods Patients（84 cases） with hypertensive cerebral hemorrhage in Affiliated Hospital of Armed Police Logistics College from January 2015 to June 2016 were randomly divided into control and treatment groups, and each group had 42 cases. Patients in two groups were treated with minimally invasive puncture, and injected Urokinase for injection into the intracavity of hematoma, added into 100 000 unit normal saline 5 m L, open drainage after 2 — 3 h retention, extubation after removal of hematoma（about 5 d）. After surgery, patients in the control group were iv administered with 5% glucose solution 250 m L, once daily. Patients in the treatment group were po administered with Xingnaojing Injection on the basis of the control group, 20 m L added into normal saline 250 m L, twice daily. Patients in two groups were treated for 4 weeks. After treatment, the clinical efficacies were evaluated, and NIHSS scores and serological index in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 81.0% and 92.9%, respectively, and there was difference between two groups（P〈0.05）. After treatment, NIHSS scores in two groups were significantly decreased, and the difference was statistically significant in the same group（P〈0.05）. And the NIHSS score in the treatment group was significantly lower than that in the control group, with significant difference between two groups（P〈0.05）. After treatment, the levels of CRP, TNF-α, and MIF in two groups were significantly decreased, but the levels of IGF-1 in two groups were significantly increased, and the difference was statistically significant in the same group（P〈0.05）. And the serological indexes in the treatment group were significantly better than those in the control group, with significant difference between two groups（P〈0.05�

关 键 词：醒脑静注射液 注射用尿激酶 高血压脑出血 神经功能缺损 NIHSS评分 血清学指标 

分 类 号：R971[医药卫生—药品]